Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor.

[1]  I. Solaroglu,et al.  Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives , 2022, Cancers.

[2]  P. Pomorski,et al.  P2X7 receptor: the regulator of glioma tumor development and survival , 2021, Purinergic Signalling.

[3]  Xiaozhuo Chen,et al.  Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer , 2021, Cancer drug resistance.

[4]  A. Costa,et al.  Adenosine Inhibits Cell Proliferation Differently in Human Astrocytes and in Glioblastoma Cell Lines , 2021, Neuroscience.

[5]  S. Muench,et al.  Structural basis for the functional properties of the P2X7 receptor for extracellular ATP , 2021, Purinergic Signalling.

[6]  F. Di Virgilio,et al.  P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy , 2021, Purinergic Signalling.

[7]  S. Komarova,et al.  Characterization of Potency of the P2Y13 Receptor Agonists: A Meta-Analysis , 2021, International journal of molecular sciences.

[8]  B. Ryffel,et al.  A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy , 2021, Nature Communications.

[9]  Elena De Marchi,et al.  P2X7 Variants in Oncogenesis , 2021, Cells.

[10]  F. Di Virgilio,et al.  Ectonucleotidases in Acute and Chronic Inflammation , 2021, Frontiers in Pharmacology.

[11]  Jeong Ho Lee,et al.  Genetic Architectures and Cell-of-Origin in Glioblastoma , 2021, Frontiers in Oncology.

[12]  F. Di Virgilio.  P2X7 is a cytotoxic receptor….maybe not: implications for cancer , 2020, Purinergic signalling.

[13]  F. Di Virgilio,et al.  P2X7 in Cancer: From Molecular Mechanisms to Therapeutics , 2020, Frontiers in Pharmacology.

[14]  H. Teixeira,et al.  CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model , 2020, Cancer Chemotherapy and Pharmacology.

[15]  W. Nowak,et al.  Orthosteric muscarinic receptor activation by the insect repellent IR3535 opens new prospects in insecticide-based vector control , 2020, Scientific Reports.

[16]  C. Klein,et al.  Tumor Cell Invasion in Glioblastoma , 2020, International journal of molecular sciences.

[17]  L. Ricci-Vitiani,et al.  Upregulation of Epithelial-To-Mesenchymal Transition Markers and P2X7 Receptors Is Associated to Increased Invasiveness Caused by P2X7 Receptor Stimulation in Human Glioblastoma Stem Cells , 2019, Cells.

[18]  C. Yoshioka,et al.  Full-Length P2X7 Structures Reveal How Palmitoylation Prevents Channel Desensitization , 2019, Cell.

[19]  E. Jimenez-Mateos,et al.  Regulation of P2X7 receptor expression and function in the brain , 2019, Brain Research Bulletin.

[20]  I. Novak,et al.  Role of the P2X7 receptor in the pathogenesis of type 2 diabetes and its microvascular complications. , 2019, Current opinion in pharmacology.

[21]  K. Drummond,et al.  The role of microglia and P2X7 receptors in gliomas , 2019, Journal of Neuroimmunology.

[22]  N. Desai,et al.  Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects , 2019, Stem Cell Reviews and Reports.

[23]  Camila Guerra Martinez.  P2X7 receptor in cardiovascular disease: The heart side , 2019, Clinical and experimental pharmacology & physiology.

[24]  P. Canoll,et al.  CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling , 2019, The Journal of Neuroscience.

[25]  T. Virolle,et al.  Extracellular adenosine promotes cell migration/invasion of Glioblastoma Stem-like Cells through A3 Adenosine Receptor activation under hypoxia. , 2019, Cancer letters.

[26]  M. Coelho,et al.  Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug‐membrane interaction for Glioblastoma Multiforme therapy , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  T. Wurdinger,et al.  An Experimenter's Guide to Glioblastoma Invasion Pathways. , 2018, Trends in molecular medicine.

[28]  F. Di Virgilio,et al.  Extracellular ATP and P2 purinergic signalling in the tumour microenvironment , 2018, Nature Reviews Cancer.

[29]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[30]  D. Wion,et al.  Reprogramming glioma cell cultures with retinoic acid: Additional arguments for reappraising the potential of retinoic acid in the context of personalized glioma therapy , 2018 .

[31]  M. Ji,et al.  Involvement of P2X7 Receptor in Proliferation and Migration of Human Glioma Cells , 2018, BioMed research international.

[32]  Y. Liu,et al.  Hypermethylation downregulates P2X7 receptor expression in astrocytoma , 2017, Oncology letters.

[33]  A. Ventura,et al.  Nucleotide P2Y13-stimulated phosphorylation of CREB is required for ADP-induced proliferation of late developing retinal glial progenitors in culture. , 2017, Cellular signalling.

[34]  C. Tasca,et al.  Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells , 2017, Purinergic Signalling.

[35]  R. Sluyter.  The P2X7 Receptor. , 2017, Advances in experimental medicine and biology.

[36]  Sang Y Lee.  Temozolomide resistance in glioblastoma multiforme , 2016, Genes & diseases.

[37]  Moriah L. Szpara,et al.  Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line. , 2016, Journal of visualized experiments : JoVE.

[38]  F. Cavaliere,et al.  Purinergic signaling: a common pathway for neural and mesenchymal stem cell maintenance and differentiation , 2015, Front. Cell. Neurosci..

[39]  L. Ricci-Vitiani,et al.  Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells , 2015, Purinergic Signalling.

[40]  M. J. van den Bent,et al.  Chemotherapy in glioma. , 2015, CNS oncology.

[41]  W. Delprado,et al.  Non-Functional P2X7: A Novel and Ubiquitous Target in Human Cancer , 2014 .

[42]  Chae-Yong Kim,et al.  Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea , 2014, Journal of Korean medical science.

[43]  F. Di Virgilio,et al.  Purinergic signalling and cancer , 2013, Purinergic Signalling.

[44]  David Ryan Koes,et al.  Lessons Learned in Empirical Scoring with smina from the CSAR 2011 Benchmarking Exercise , 2013, J. Chem. Inf. Model..

[45]  G. Lenz,et al.  Purinergic signaling in glioma progression. , 2013, Advances in experimental medicine and biology.

[46]  S. Ceruti,et al.  Adenosine signaling in glioma cells. , 2013, Advances in experimental medicine and biology.

[47]  M. Campos,et al.  P2X7 receptor activation leads to increased cell death in a radiosensitive human glioma cell line , 2012, Purinergic Signalling.

[48]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[50]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[51]  D. Donnelly-roberts,et al.  Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors , 2009, British journal of pharmacology.

[52]  G. Burnstock,et al.  Effect of extracellular ATP on the growth of hormone‐refractory prostate cancer in vivo , 2008, BJU international.

[53]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[54]  G. Burnstock.  Pathophysiology and Therapeutic Potential of Purinergic Signaling , 2006, Pharmacological Reviews.

[55]  M. Dujovny,et al.  Differentiation-inducing activity of neomycin in cultured rat glioma cells , 2004, Neurological research.

[56]  R. Rodnight,et al.  Extracellular Nucleotides and Nucleosides Induce Proliferation and Increase Nucleoside Transport in Human Glioma Cell Lines , 2003, Journal of Neuro-Oncology.

[57]  G. Burnstock,et al.  Cellular distribution and functions of P2 receptor subtypes in different systems. , 2004, International review of cytology.

[58]  G. Weisman,et al.  Purine signaling and potential new therapeutic approach: possible outcomes of NTPDase inhibition. , 2002, Current drug targets.

[59]  G. Lambrecht.  Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[60]  J. Spychała.  Tumor-promoting functions of adenosine. , 2000, Pharmacology & therapeutics.

[61]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[62]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .